You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《業績》安進藥廠(AMGN.US)季績勝預期 輕微上調全年業績指引
阿思達克 08-06 11:55
道指成分股,美國安進藥廠(AMGN.US)公布第二季業績。季度淨利潤按年升92%至14.32億美元,每股季度攤薄利潤2.65美元,經調整後為每股6.02美元,高於市場預期的5.29美元。季度收入按年升9%至91.79億美元,高於市場預期的89.4億美元。 公司上調全年度經調整每股盈利指引,由20至21.2美元上調至20.2至21.3美元,市場預典為20.91美元。收入指引亦由343億至357億美元上調至350億至360億美元,市場預期為354億美元。 降膽固醇藥Repatha銷售額增長31%至6.96億美元。骨骼藥物Prolia銷售額跌4%至11億美元,公司表示,由於生物相似藥的新競爭,預計今年銷售額將進一步下滑。公司又指,預計第四季度得兩項關鍵中期MariTide研究數據。一項研究在肥胖或超重成年人測試該藥,另一項研究則探討MariTide作為第二型糖尿病治療藥物的效果。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account